Differences and similarities of multiple sclerosis (MS) in adults and children have been a focus of research in recent years. 1, 2 Clinically, MS in children is more likely to show a polysymptomatic onset, and sometimes initial symptoms include acute disseminated encephalomyelitis (ADEM) characterized by encephalopathy. Although ADEM and MS are considered autoimmune diseases of the CNS, the targets of the immune response are still largely uncertain. Several studies have demonstrated that in childhood demyelinating diseases, autoantibodies to myelin oligodendrocyte glycoprotein (MOG) are present in high titers, especially in younger children, while they are only rarely observed in adult patients with MS. 3, 4 Recently, an antibody to the inward rectifying potassium channel KIR 4.1 was identified in adult patients with MS. 5 The aims of the current study were to address the occurrence of antibodies to KIR4.1 (KIR4.1-IgG) in children with acquired demyelinating disease (ADD) and the relation of autoantibodies to KIR4.1 and MOG.
METHODS Standard protocol approvals, registrations, and patient consents. ELISA to determine KIR4.1-specific antibodies. We used the same methodology to measure KIR4.1-specific antibodies by ELISA as the one used in a previous study. 5 HEK cells were transfected with C-terminal his-tagged KIR4.1 by reversed transfection. Cells were lysed and KIR4.1 protein isolated by cobalt bead-based affinity purification (Thermo Scientific, Waltham, MA). Successful purification of oligomeric KIR4.1 protein was validated by a gel filtration column (GE Biosciences, Pittsburgh, PA). The quality of the oligomeric protein, reflecting the posttranslational modifications of KIR4.1 protein expressed in white matter, was determined on 4% to 12% bis-tris gel (Invitrogen, Carlsbad, CA) with reducing and nonreducing conditions along with blue native gel (Invitrogen). Freshly purified protein was used in all assays because KIR4.1 protein was prone to aggregation at 4°C or in freezing/thawing cycles. Sera were diluted 1:100 and blinded to the person performing the assay. All sera and the sera to determine the cutoff were measured in the same assay. None of the samples used in the assays were thawed and refrozen. The coefficients for interassay (3.41% 6 0.86%) and intraassay (0.97% 6 0.36%) variation were within permitted limits of variance. The cutoff value was determined in each assay by the optical density (OD) obtained from the same sera of 37 HC donors (mean 1 5 SDs). Therefore, the cutoff varied slightly from assay to assay.
Four KIR4.1-IgG-positive sera and KIR4.1-IgG-negative other neurologic disease (OND) sera were analyzed by immunohistochemistry for binding to human brain tissue sections as described previously. 5 Capture ELISA to determine KIR4.1-specific antibodies.
For sandwich ELISA, KIR4.1 oligomeric protein was also used (see above). Linear titration was performed to determine the optimal amount of monoclonal antibody coating along with sample matrix optimization with standard spiked and recovery assay. For final assay amino link (Thermo Scientific), plates were coated with 50 mL of 1.5 mg monoclonal anti-KIR4.1 antibody (Sigma) per milliliter and left overnight at 4°C with mild shaking. Plates were washed 5 times with washing buffer (0.05% Tween 20 with phosphate-buffered saline) and blocked with 200 mL of sample buffer (0.5% milk in washing buffer) at room temperature for 1 hour. Blocked plates were incubated with 50 mL of purified KIR4.1 (200 ng) in sample buffer for 2 hours at room temperature with mild shaking. After 2 hours, plates were washed 5 times with washing buffer. Washed plates were incubated with 50 mL of serum sample (1 mL serum/100 mL sample buffer) for 2 hours at room temperature. Subsequently, plates were washed with washing buffer 5 times and incubated with 50 mL of anti-human rabbit secondary antibody (Sigma) with dilution of 1:10,000 in sample buffer for 1 hour at room temperature. Plates were washed again 5 times and developed with 100 mL of stabilized TMB chromogen for 20 minutes. Subsequently, reactions were stopped with 50 mL of 1 N sulfuric acid. Control ELISA plates were incubated with purified aquaporin-4 protein to anti-KIR4.1 monoclonal antibody-coated plates and further assays were performed in the same manner. OD measurements were performed at 450 nm on a microplate reader (Tecan, Männedorf, Switzerland). All assays were run in triplicate, and the average delta OD was considered for final analysis after background subtraction from control antigen plates. The serum of 3 patients was no longer available for testing by capture ELISA (1 ADEM, 1 autoimmune disease, 1 HC).
MOG-specific antibodies. MOG-specific antibodies in sera of patients with ADD were measured using a cell-based bioassay based on a MOG-transfected glioma cell line as previously described. 4 The serum of one patient with ADEM was not available for testing. Serum was added in a final dilution of 1:100.
Statistical analysis. KIR4.1-IgG titers were compared among different groups using the Kruskal-Wallis and Dunn multiple comparison tests. KIR4.1-IgG titers were considered positive if they exceeded the cutoff defined by the mean and 5 SDs of 37 sera from independent OND controls that have also been used in previous assays. 5 KIR4.1-IgG, age, and MOG-IgG were compared using a nonparametric Spearman correlation. A p value ,0.05 was considered significant. RESULTS KIR4.1-specific antibodies are present in the serum from children with ADD of the CNS. Serum samples from 47 children with ADD, 22 with OND, and 22 with autoimmune disease, and from 18 HCs were tested for KIR4.1-IgG by ELISA. Antibody reactivities were significantly higher in patients with ADD compared with HCs and patients with autoimmune disease (p , 0.0001, figure 1A) . Twenty-seven patients with ADD were KIR4.1-positive (57.45%), whereas none of the controls had a serum titer above the cutoff. Similar results were obtained when we used a capture ELISA to determine antibodies to KIR4.1. Antibody reactivities were significantly higher in patients with ADD compared with HCs and patients with OND and autoimmune disease (p , 0.0001; figure e-1A).
We also stained human brain tissue sections with serum IgG of patients with ADD and OND control sera. A specific binding to CNS cells, most likely oligodendrocytes and astrocytes, similar to the pattern seen in adult patients, was observed for the ADD but not for the OND sera (figure e-2). 5 We conclude that serum KIR4.1-IgG is found in a majority of children with ADD but not in children with other diseases or in healthy children. These antibodies bind KIR4.1 in the brain similar to KIR4.1-IgG from adult patients with MS.
Anti-KIR4.1-IgG titer in children with MS, CIS, ADEM, and MDEM. Serum KIR4.1-IgG was found in more than 50% of children with MS or CIS ( figure 1B) . No difference was observed between children with CIS/MS and DEM (comprising ADEM and MDEM), although the number of patients was low. Two patients with isolated optic neuritis were KIR4.1-positive, and one patient was negative. Of the 8 patients with CIS, 4 developed MS during the study period from 2009 to 2012 and 3 of them had high serum KIR4.1-IgG ( figure 1B) . Similar results were obtained by capture ELISA (figure e-1A) .
Altogether, we found no major differences in KIR4.1-IgG serum titers in children with CIS, MS, or ADEM/MDEM. In summary, KIR4.1-IgG antibodies, in contrast to MOG antibodies, are not age-dependent. The lack of correlation between anti-MOG and anti-KIR4.1 antibodies suggests that the formation of these autoantibodies is a specific event in a subset of patients with ADD. DISCUSSION Recently, a serum antibody to KIR4.1 was identified in adult patients with MS. Almost half of the patients had serum KIR4.1-IgG, while the antibody was only rarely found in patients with OND. 5 The antibody binds to the first extracellular domain of KIR4.1. Transfer experiments in mice have shown that KIR4.1-IgG induces loss of Kir4.1 and complement activation in vivo. KIR4.1 is an inward rectifying potassium channel expressed on oligodendrocytes and astrocytes. The channel contributes to the maintenance of the electrochemical gradient by removing potassium from the extracellular space. 7 Kir4.1 knock-out mice show hypomyelination of the spinal cord and axonal degeneration, leading to severe motor deficits. 8 Mutations of the KIR4.1 gene (KCNJ10) in humans cause SeSAME or EAST syndrome characterized by epilepsy, ataxia, sensorineural deafness, and tubulopathy. 9 We identified serum antibodies to KIR4.1 in 57.45% of children with ADD of the CNS. KIR4.1-IgG was Serum reactivity to KIR4.1 in children predominantly found in children with MS or CIS, although 1 of 3 children with DEM also reacted to KIR4.1. The prevalence and distribution of KIR4.1-IgG in children with MS/CIS is similar to the prevalence observed in adult patients. Multiple previous studies have focused on antibodies to MOG, another potential autoantigen in ADD of the CNS. Highest titers of anti-MOG antibodies are found in young children with ADD and are only rarely seen in older children or even adult patients with MS. 3,4,10,11 KIR4.1-IgG was not age-dependent and did not correlate with MOG antibody responses. Therefore, KIR4.1-IgG and MOG-IgG seem to characterize different subgroups of patients. MOG-IgG occurs predominantly before the age of 10 years in ADD and seems to characterize a subset of patients that are distinct from adult MS. By contrast, KIR4.1 antibodies are found in older children and adult patients with MS, suggesting similarities between these 2 groups.
